The results, published on Tuesday in The Lancet Infectious Diseases Journal, add to the number of vaccine candidates under trial that have been found safe. The Chinese trial involved more than 700 volunteers recruited in China between April 16 and May 5. “The vaccine appeared to be safe and well tolerated at all tested doses. The study also identified the optimum dose to generate the highest antibody responses, while taking account of side effects and production capacity: 3µg. But even then, after phase 3 trial completion and after licensure, we should prudently remain cautious.”

Source: Hindustan Times November 17, 2020 23:52 UTC